Literature DB >> 19589692

Is tricuspid valve replacement a catastrophic operation?

Kiick Sung1, Pyo Won Park, Kay-Hyun Park, Tae-Gook Jun, Young Tak Lee, Ji-Hyuk Yang, Wook Sung Kim, Joomin Hwang.   

Abstract

OBJECTIVE: Tricuspid valve replacement (TVR) has a high postoperative mortality, despite recent advances in perioperative care. We report the results of our experience in TVR with an emphasis on early mortality and morbidity and long-term follow-up.
METHODS: Between October 1994 and August 2007, 80 consecutive TVRs were performed in 78 patients. The mean age was 48+/-14 (range: 20-70) years. The underlying disease of the patients was classified as rheumatic (n=54), congenital (n=12), endocarditis (n=10) or degenerative (n=4). Previous cardiac surgery had been performed in 40 patients (50%). Isolated TVR was performed in 24 patients (30%).
RESULTS: Hospital mortality occurred in one patient (1.4%). Postoperative morbidities included intra-aortic balloon pump (n=5), bleeding re-operation (n=4), delayed sternal closure (n=3), acute renal failure (n=3), subdural haematoma (n=3), extracorporeal membrane oxygenation (n=1), mediastinitis (n=1) and pacemaker insertion (n=4). In 42 patients, ventilator support was needed for more than 72 h. Based on multivariate analysis, age (p<0.001) and the cardiopulmonary time (p=0.004) were the identified risk factors. Follow-up was completed in all patients with a mean duration of 56+/-37 (range: 0-158) months. During the follow-up period, there were seven deaths (8.8%), including five cardiac deaths. The 5- and 8-year survival rates were 95+/-3% and 79+/-9% and event-free survival rates were 76+/-6% and 61+/-9%, respectively. Based on multivariate analysis, the only identified predictors of late deaths was a postoperative low cardiac output (p=0.024).
CONCLUSIONS: TVR can be performed and low operative mortality can be achieved thorough optimal perioperative management in the current era.

Entities:  

Mesh:

Year:  2009        PMID: 19589692     DOI: 10.1016/j.ejcts.2009.04.063

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  8 in total

1.  Surgical outcomes of isolated tricuspid valve procedures: repair versus replacement.

Authors:  Julius I Ejiofor; Robert C Neely; Maroun Yammine; Siobhan McGurk; Tsuyoshi Kaneko; Marzia Leacche; Lawrence H Cohn; Prem S Shekar
Journal:  Ann Cardiothorac Surg       Date:  2017-05

Review 2.  Evidence-based surgical management of acquired tricuspid valve disease.

Authors:  Sung Ho Shinn; Hartzell V Schaff
Journal:  Nat Rev Cardiol       Date:  2013-02-12       Impact factor: 32.419

3.  Lost without Occam's razor: Escherichia coli tricuspid valve endocarditis in a non-intravenous drug user.

Authors:  Jo-Ai Foley; Daniel Augustine; Richard Bond; Kate Boyce; David Maciver
Journal:  BMJ Case Rep       Date:  2010-08-10

4.  Ten-year experience of tricuspid valve replacement with the St. Jude medical valve.

Authors:  Xiliang Zhu; Yi Luo; Eryong Zhang; Qi An; Xijun Xiao; Li Dong; Yingqiang Guo; Ke Dian; Zhong Wu
Journal:  Sci Rep       Date:  2018-11-09       Impact factor: 4.379

Review 5.  Minimally invasive tricuspid valve surgery.

Authors:  Abdelrahman Abdelbar; Ayman Kenawy; Joseph Zacharias
Journal:  J Thorac Dis       Date:  2021-03       Impact factor: 2.895

6.  Determinants of Morbidity and Mortality Associated With Isolated Tricuspid Valve Surgery.

Authors:  Akram Kawsara; Fahad Alqahtani; Vuyisile T Nkomo; Mackram F Eleid; Sorin V Pislaru; Charanjit S Rihal; Rick A Nishimura; Hartzell V Schaff; Juan A Crestanello; Mohamad Alkhouli
Journal:  J Am Heart Assoc       Date:  2021-01-05       Impact factor: 5.501

7.  Clinical results of tricuspid valve replacement - a 21-case report.

Authors:  Yu Zhuang; Jie Zhou; Mingdi Xiao; Zhongxiang Yuan; Chengbao Lu; Min Yu; Lei Lin
Journal:  J Biomed Res       Date:  2010-01

8.  Comparative early outcomes of tricuspid Valve repair versus replacement for secondary tricuspid regurgitation.

Authors:  Mohamad Alkhouli; Chalak Berzingi; Amer Kowatli; Fahad Alqahtani; Vinay Badhwar
Journal:  Open Heart       Date:  2018-09-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.